We examined the macrophages infiltration in tumors at 8-week when tumor acquired resistance to bevacizumab, whereas CD68+ CD206+ for classic M2 macrophage and CD68+ CD86+ for M1 macrophage. The gene discussed is CD86; the disease is neoplasm.